# US 2022/0087947 A1 · Nanoparticle for delivering ribonucleoprotein and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0087947 A1
- Document ID: US20220087947A1
- Status: Published application
- Kind: A1
- Application number: 17/384,913
- Filed: 2021-07-26
- Published: 2022-03-24
- Earliest claimed: 2020-09-17
- Assignees: Korea Institute of Science and Technology
- Applicants: Korea Institute of Science and Technology
- Inventors: Hyojin LEE; Seongchan KIM; Youngdo JEONG
- Web page: https://patentgrep.com/patent/US20220087947A1

## CPC

- A61K 9/5115: {Inorganic compounds}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- A61K 47/6923: {the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb}
- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- C12N 15/90: Stable introduction of foreign DNA into chromosome
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/1138: {against receptors or cell surface proteins}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2320/31: Combination therapy
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are a surface-aminated mesoporous silica nanoparticle, a method of preparing the same, use of the nanoparticle for delivering a ribonucleoprotein, and use of the nanoparticle for the prevention or treatment of cancer. The surface-aminated mesoporous silica nanoparticle may be loaded with large RNPs such as Cas9-RNP, and thus may be applied to treatment of various diseases treatable by gene editing.

## Claims

### Claim 1

A surface-aminated mesoporous silica nanoparticle which has a mean pore size of about 15 nm to about 50 nm and is capable of being loaded with ribonucleoprotein (RNP).

### Claim 2 (depends on 1)

The surface-aminated mesoporous silica nanoparticle of claim 1, wherein the nanoparticle has a diameter of about 150 nm to about 1000 nm.

### Claim 3 (depends on 1)

The surface-aminated mesoporous silica nanoparticle of claim 1, wherein the nanoparticle has a zeta potential of about +20.0 mV to about +30.0 mV.

### Claim 4 (depends on 1)

The surface-aminated mesoporous silica nanoparticle of claim 1, wherein the nanoparticle has an RNP loading capacity of about 10% (w/w) to about 20% (w/w) at pH 7.4.

### Claim 5 (depends on 1)

The surface-aminated mesoporous silica nanoparticle of claim 1, wherein the nanoparticle has a higher drug release rate under an acidic pH condition of pH 6.5 or less than a drug release rate of the nanoparticle under a neutral pH condition of pH 7.0 to pH 8.0.

### Claim 6 (depends on 1)

The surface-aminated mesoporous silica nanoparticle of claim 1, wherein the nanoparticle exhibits a drug release rate of 5% or less under a neutral pH condition of pH 7.0 to pH 8.0 for 12 hours, and a drug release rate of 30% or more under an acidic pH condition of pH 6.5 or less for 12 hours.

### Claim 7 (depends on 1)

The surface-aminated mesoporous silica nanoparticle of claim 1, wherein the nanoparticle releases RNP to cytoplasm in vivo.

### Claim 8 (depends on 1)

The surface-aminated mesoporous silica nanoparticle of claim 1, wherein the RNP is a Cas protein-RNP.

### Claim 9 (depends on 8)

The surface-aminated mesoporous silica nanoparticle of claim 8, wherein the Cas protein of the Cas protein-RNP is Cas9, nickase Cas9 (nCas9), deactivated Cas9 (dCas9), nCas9 fused to cytidine deaminase, nCas9 fused to adenine deaminase, dCas9 fused to cytidine deaminase, dCas9 fused to adenine deaminase, Cas12, Cas13, Cpf1, C2c2, or a combination of two or more thereof.

### Claim 10 (depends on 8)

The surface-aminated mesoporous silica nanoparticle of claim 8, wherein the Cas protein-RNP is Cas9-RNP or Base editor-RNP.

### Claim 11 (depends on 10)

The surface-aminated mesoporous silica nanoparticle of claim 10, wherein the Cas protein-RNP is one type or two or more types.

### Claim 12 (depends on 10)

The surface-aminated mesoporous silica nanoparticle of claim 10, wherein the Cas9-RNP is two types, wherein any one type thereof comprises sgRNA targeting fibroblast growth factor receptor 3 (FGFR3), and
the other type thereof comprises sgRNA targeting transforming acidic coiled-coil containing protein 3 (TACC3).

### Claim 13 (depends on 12)

The surface-aminated mesoporous silica nanoparticle of claim 12, wherein the sgRNA targeting FGFR3 comprises any one nucleotide sequence of SEQ ID NOS: 3 to 5 and
the sgRNA targeting TACC3 comprises any one nucleotide sequence of SEQ ID NOS: 6 to 8.

### Claim 14 (depends on 1)

The surface-aminated mesoporous silica nanoparticle of claim 1, wherein the surface-aminated mesoporous silica nanoparticle is prepared by a method comprising:
(1) dissolving a cationic surfactant in a basic solution;
(2) adding a silica precursor solution to the solution prepared in (1) and stirring the mixture to prepare a porous silica nanoparticle;
(3) adding a benzenoid compound solution to the porous silica nanoparticle and allowing the same to react to prepare a mesoporous silica nanoparticle; and
(4) adding an amine compound solution to the mesoporous silica nanoparticle to prepare a mixture, and refluxing the mixture to prepare the surface-aminated mesoporous silica nanoparticle.

### Claim 15 (depends on 14)

The surface-aminated mesoporous silica nanoparticle of claim 14,
wherein in (1), the cationic surfactant is cetyl trimethyl ammonium bromide (CTAB) or cetyl trimethyl ammonium chloride (CTAC);
in (2), the silica precursor is tetramethyl orthosilicate (TMOS) or tetraethyl orthosilicate (TEOS);
in (3), the benzenoid compound is any one or more selected from the group consisting of benzene, trimethylbenzene (TMB), 1,3,5-triethylbenzene (TEB), 1,3,5-tri-tert-butylbenzene (TtBB), and 1,3,5-Triisopropylbenzene (TiPB); and
in (4), the amine compound is any one or more selected from the group consisting of 3-aminopropyltriethoxysilane (APTES), N(beta-aminoethyl)gamma-aminopropylmethyldimethoxysilane (AEAPMDMS), N-[3-(trimethoxysilyl)propyl]ethylenediamine, N1-(3-trimethoxysilylpropyl)diethylenetriamine, (3-aminopropyl)trimethoxysilane, N-[3-(trimethoxysilyl)propyl]aniline, trimethoxy[3-(methylamino)propyl]silane, 3-(2-aminoethylamino)propyldimethoxymethylsilane, trimethoxysilylpropyl modified polyethylenimine (TPPI), p-aminophenyltrimethoxysilane, and 1-amino-2-(dimethylethoxysilyl)propane.

### Claim 16 (depends on 1)

A pharmaceutical composition for preventing or treating cancer, the pharmaceutical composition comprising the surface-aminated mesoporous silica nanoparticle of claim 1,
wherein Cas9-RNP loaded onto the nanoparticle is two types, and any one thereof comprises sgRNA targeting fibroblast growth factor receptor 3 (FGFR3), and the other type thereof comprises sgRNA targeting transforming acidic coiled-coil containing protein 3 (TACC3).

### Claim 17 (depends on 16)

The pharmaceutical composition of claim 16, wherein
the sgRNA targeting FGFR3 comprises any one nucleotide sequence of SEQ ID NOS: 3 to 5, and
the sgRNA targeting TACC3 comprises any one nucleotide sequence of SEQ ID NOS: 6 to 8.

### Claim 18 (depends on 16)

The pharmaceutical composition of claim 16, wherein the cancer is selected from the group consisting of glioblastoma, lung adenocarcinoma, squamous cell lung carcinoma, head and neck squamous cell carcinoma, bladder cancer, cervical cancer, breast invasive ductal carcinoma, urothelial carcinoma, malignant glioma, and glioma.

### Claim 19 (depends on 16)

A method of preventing or treating a disease, the method comprising administering an effective amount of the pharmaceutical composition of claim 16 to a subject in need thereof.
